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Abstract:  The pathological actions of anthrax toxin require the activities of its  edema 
factor (EF) and lethal factor (LF) enzyme components, which gain intracellular access via 
its receptor-binding component, protective antigen (PA). LF is a metalloproteinase with 
specificity for selected mitogen-activated protein kinase kinases (MKKs), but its activity is 
not directly lethal to many types of primary and transformed cells in vitro. Nevertheless,  
in vivo treatment of several animal species with the combination of LF and PA (termed 
lethal toxin or LT) leads to morbidity and mortality, suggesting that LT-dependent toxicity 
is mediated by cellular interactions between host cells. Decades of research have revealed 
that a central hallmark of this toxicity is the disruption of key cellular barriers required to 
maintain homeostasis. This review will focus on the current understanding of the effects of 
LT  on  barrier  function,  highlighting  recent  progress  in  establishing  the  molecular 
mechanisms underlying these effects. 
Keywords:  anthrax  lethal  toxin;  barrier  function;  bacteria;  infection;  intestine; 
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1. Introduction  
Anthrax  toxin  is  an  essential  virulence  factor  for  Bacillus  anthracis,  the  causative  pathogen 
underlying anthrax infection, whose proximal mechanisms of action have been recently reviewed [1,2]. 
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This  toxin  is  composed  of  three  subunits,  edema  factor  (EF),  lethal  factor  (LF),  and  protective  
antigen  (PA).  EF  has  adenylate  cyclase  activity  resulting  in  tissue  edema,  whereas  LF  is  a  zinc 
metalloproteinase that targets specific mitogen-activated protein kinase kinases (MKKs). These toxin 
enzymes require the host receptor-binding component of anthrax toxin, PA, for intracellular entry into 
target cells. Much research attention has focused on the biology of anthrax LF, which when combined 
with its receptor-binding partner, PA, is termed lethal toxin (LT). Administration of purified LT to 
mice recapitulates many of the major clinical features of anthrax infection [3]. Although anthrax LT 
can result in the caspase-1-dependent  release of cytokines such  as IL-1β and IL-18, this  effect is 
species- and strain-specific [3–5]. Instead, the predominant effect of anthrax toxin on the immune 
system is to cause immunosuppression [2,6], allowing very high concentrations of Bacillus anthracis 
to accumulate in the host, thereby increasing the likelihood of future rounds of infection. Although this 
immunosuppression facilitates infection, it does not explain the deleterious effects of LT that occur 
independent of infection.  
One central feature of intoxication is the compromise of host barrier integrity. Although the lethal 
effects of fractionated LT were first described by Stanley and Smith in early 1961 [7], subsequent 
studies  performed  at  Fort  Detrick  during  the  1960’s  provided  further  insights  into  the  underlying 
pathogenic  mechanisms  [8,9].  These  studies  revealed  that  LT  has  a  deleterious  effect  on  barrier 
function  in  rats,  leading  to  lethal  pulmonary  edema  and  hemoconcentration.  A  comprehensive 
examination of the mechanisms underlying in vivo lethality with recombinant LT was not undertaken 
until 2003 by Moayeri et al. [3]. This murine study revealed that anthrax LT administration results in 
multiple signs of host barrier dysfunction, including splenic hemorrhage, fecal blood, and pleural and 
peritoneal edema [3]. More recent investigations have documented the effects of LT on the integrity of 
the  endothelial  cell  barriers  that  line  blood  vessels  and  epithelial  barriers  that  protect  the 
gastrointestinal and respiratory tracts [10–13]. The effects of LT on barrier function not only contribute 
to the spread of infection, but also disrupt physiological homeostasis. This article will provide an 
overview of the effects  of anthrax LT on a variety of host tissue barriers, as well as our current 
understanding of the pathogenic mechanisms underlying these effects. 
2. Epithelial and Endothelial Barriers  
Host barriers are essential for maintaining physiological homeostasis, by establishing functional 
boundaries  between  the  host  and  its  environment  or  between  different  tissue  types  or  body  
cavities  [14].  These  boundaries  facilitate  the  development  of  molecular  gradients  between  tissue 
compartments, as well as provide protection from potentially harmful organisms and molecules located 
in the adjacent environment. Epithelial and endothelial tissues have several features that contribute to 
their barrier function. Luminal secretions such as mucus commonly coat the outermost surface of host 
barriers, forming a physical and chemical barrier to pathogens and large molecules. The mucus layer 
overlies the central structure of the barrier, a single layer of specialized endothelial or epithelial cells, 
whose  lipid  plasma  membranes  and  highly  specific  membrane  transport  systems  regulate 
transepithelial  and/or  transendothelial  passage  of  most  molecules.  Adhesive  junctional  complexes 
between epithelial or endothelial cells are required to maintain an effective barrier, and have been a 
topic of detailed reviews [15,16]. Tight junction (TJ) and adherens junction (AJ) complexes consist of Toxins 2011, 3                         
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transmembrane  proteins  that  link  adjacent  cells  to  the  actin  cytoskeleton  through  cytoplasmic 
scaffolding proteins. TJs are located most apically and are responsible for sealing the intercellular 
space, regulating selective paracellular ionic solute transport, and maintaining cell polarity. AJs are 
formed by cadherin-catenin interactions and are important in the mechanical linkage of adjacent cells. 
TJs  and  AJs  are  also  important  in  the  regulation  of  cellular  proliferation,  polarization,  and 
differentiation. Desmosomes, which exist between epithelial cells (but not endothelial cells), provide 
additional mechanical linkages between neighboring epithelial cells. At their basal surfaces, epithelial 
or  endothelial  cells  are  anchored  to  the  underlying  basal  lamina  (basement  membrane)  through  
cell-matrix adhesions [17]. Epithelial layers are avascular and are nourished by substances diffusing 
from  the  blood  vessels  into  the  underlying  tissue.  The  basement  membrane  acts  as  a  selectively 
permeable  membrane,  determining  which  substances  enter  the  epithelium  through  this  direction. 
Subepithelial connective, nervous, and muscular tissues minimally contribute to the permeability of 
epithelial and endothelial barriers [18,19]. 
3. Host Barriers Breached by Bacillus anthracis during Infection 
The  natural  cycle  of  Bacillus  anthracis  infection  has  been  reviewed  extensively  [20,21].  The 
infection cycle generally involves herbivores, which are infected following exposure to spores present 
in the soil during feeding. Upon death of the animal, large numbers of bacteria are released into the 
soil where they sporulate, forming the basis for the next round of infection. Humans become infected 
with  Bacillus  anthracis  when  exposed  to  infected  animal  products,  through  either  handling  or 
consumption.  Anthrax  infection  can  also  occur  following  exposure  to  aerosolized  spores  during 
manufacturing with animal products (e.g., leather processing) or by the malevolent actions of their own 
species, as highlighted by the U.S. bioterrorism attacks of 2001 [22]. 
Anthrax  infection  can  take  on  three  distinct  clinical  forms:  cutaneous,  inhalation,  and 
gastrointestinal. The manifestation of a specific form is dependent upon the route of infection. Despite 
differences in their clinical presentations, these clinical syndromes share one important feature, each 
requires the penetration of protective host barriers by Bacillus anthracis. 
Cutaneous anthrax is the most common form of anthrax infection, comprising nearly 95% of all 
human  anthrax  infections  [21,23].  This  form  of  anthrax  occurs  when  Bacillus  anthracis  spores 
penetrate the dermal layers  of the skin, usually  through a cut  or abrasion.  Local  edema becomes 
apparent 24–48 h post infection as a result of spore germination and toxin production. Approximately 
two days post infection, patients typically develop a large round ulcer, which is followed shortly by the 
formation of a characteristically painless, depressed black eschar. In some cases, the infection breaches 
the epithelial layers of the skin, entering into the lymphatic system. Once this breach occurs, patients 
may develop lymphangitis and lymphadenopathy with subsequent systemic complications. In these 
rare cases, the infection can lead to septicemia, shock, hemolytic anemia, coagulopathy, hyponatremia, 
renal failure, and death. Anthrax infection has also been acquired trans-cutaneously in injection drug 
abusers. In these cases, the ensuing soft tissue infection is not necessarily accompanied by eschar 
formation, rendering the diagnosis more difficult [24,25]. 
Gastrointestinal  anthrax occurs  when a large number of vegetative  bacilli are ingested, usually 
through the consumption of infected, but insufficiently cooked meat [21]. Differential manifestations Toxins 2011, 3                         
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of  the  infection  are  observed  depending  on  whether  the  upper  or  lower  gastrointestinal  tracts  are 
involved. If infection occurs in the upper gastrointestinal tract or oropharyngeal tract, patients develop 
oral or esophageal ulcers. These lesions can, in turn, progress to regional lymphadenopathy, edema, 
and sepsis, in a similar fashion as cutaneous anthrax. Infection in the lower gastrointestinal tract often 
leads to lesions in the terminal ileum or cecum [23]. Patients subsequently develop nausea, vomiting, 
bloody diarrhea, severe gastric lesions, and, in some cases, ascites and sepsis [26]. However, cases that 
involve intestinal eschar formation with surrounding tissue edema are nearly always fatal, highlighting 
the functional importance of the intestinal barrier during infection [27]. 
Inhalation anthrax is considered to be the most serious form of anthrax infection, resulting in high 
levels of morbidity and mortality. This clinical form of anthrax ensues when Bacillus anthracis spores 
are inhaled and dispersed throughout the alveolar space. Extrapolation from animal studies suggests 
that the inhalation of 2500 to 55,000 Bacillus anthracis spores is sufficient to produce an LD50 in 
humans [28]. However, an analysis from 2002 suggested that one to three spores would be sufficient to 
cause infection (LD1), based on an LD50 of 4100–8000 spores [29]. Once germination of the spores 
ensues, inhalation anthrax has been reported to have a mortality rate as high as 89%, although the 
survival  in  the  2001  bioterrorism  cases  was  somewhat  higher  (six  out  of  the  eleven  manifested 
inhalational cases), suggesting that mortality rates can be improved with proper antibiotic treatment 
and supportive care [23,30]. Moreover, the relative ease with which spores can be aerosolized makes 
inhalation anthrax a serious concern from a bioterrorism perspective.  
In  a  typical  inhalation  infection,  spores  first  encounter  the  pulmonary  epithelium  and  are 
subsequently endocytosed by pulmonary macrophages and/or dendritic cells. Pulmonary phagocytes 
then translocate to the regional lymph nodes in the mediastinum, where germination occurs. One of the 
classic signs of inhalation anthrax is widening of the mediastinum, likely due to the production of 
anthrax toxin by bacteria germinating at this site [23,31,32]. Presumably, dissemination occurs mainly 
via the invasion of the bacteria into blood vessels surrounding the mediastinal lymph nodes. Although 
it has recently been observed in some animal model systems that germination can also occur in the 
intra-alveolar space, whether this can lead directly to dissemination is unclear [33,34].  
Systemic dissemination is possible for each of the distinct forms of clinical anthrax infection. In this 
regard, Bacillus anthracis demonstrates an intrinsic ability to compromise a variety of epithelial and 
endothelial barriers that are present in many mammalian organ systems. The initial breach is facilitated 
either by existing barrier imperfections or by the host phagocytes serving as “Trojan horses” [35]. The 
regional lymph nodes form another line of defense that is overcome, leading to invasion of the blood 
vessels and dissemination. It is widely held that the anthrax toxin released by replicating Bacillus 
anthracis  contributes  greatly  to  systemic  infection  by  disrupting  the  integrity  and  functionality  of 
various barrier tissues (Figure 1).  Toxins 2011, 3                         
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Figure 1. Lethal toxin disrupts host barriers. Lethal factor (LF) binds to membrane-bound 
protective  factor  (PA).  Following  cleavage  of  PA83  into  PA63  by  cellular  furin-like 
proteases, the heptameric pre-pore is formed. The complex is subsequently internalized 
into endosomes. Upon acidification, the structure forms a mature pore, enabling the entry 
of LF into the cytoplasm of target cells (left) [2]. Shown are schematic diagrams of key 
host barriers (center), along with the pathophysiological effects of LT on these structures 
(right). These topics are discussed in Sections 4–7. 
 
4. Effect of Anthrax LT on Endothelial Barriers  
4.1. Clinical Findings  
Important  clinical  features  of  Bacillus  anthracis  infection  in  human  subjects  include  signs  of 
increased vascular permeability: mediastinal lymphadenopathy and edema, hemorrhagic mediastinitis, 
pleural  effusions,  hemorrhagic  leptomeningitis,  and  pulmonary  edema  [36,37].  Hemorrhages  in 
multiple  organs,  gastrointestinal  bleeding,  and  vessel  inflammation  are  also  frequently  observed, 
providing further evidence of damage to the vascular endothelium. Moreover, analyses of infected 
human subjects and animal models at autopsy have shown destruction of both large and small blood 
vessels [37,38]. Anthrax LT directly induces many signs of endothelial disruption in animal models 
(e.g., in mouse, rat, rabbit, and nonhuman primates), suggesting a profound role of LT in mediating the 
disruption  of  endothelial  barrier  function.  For  example,  mice  administered  LT  display  increased 
pulmonary  vascular  permeability,  as  determined  by  direct  visualization  of  fluorescein  
isothiocyanate-dextran (FITC-dextran) diffusion into vessel walls and by quantitative measurement of 
FITC-dextran extravasation into the lungs [39]. Endothelial dysfunction in LT-treated animals results 
in hemoconcentration, pleural fluid collections, splenic hemorrhages, tissue hypoperfusion, and arterial 
hypoxemia [3,8,9,11,40]. Of note, findings of endothelial necrosis and vessel inflammation that are 
associated with systemic infection have not been reported in LT-treated mice and rats [3,40]. This Toxins 2011, 3                         
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suggests that endothelial barrier disruption during infection may result from other factors in addition to 
LT (e.g., other toxic bacterial products, species-specific effects and/or effects of edema factor (ET) or 
host factors involved in the systemic inflammatory response syndrome) (Figure 1).  
4.2. Mechanisms of Action  
Investigation of the mechanisms of action of LT-dependent endothelial toxicity has mainly involved 
the use of in vitro experimental systems. In initial studies, LT-mediated cell death was reported in 
toxin-treated  human  primary  endothelial  cells,  including  human  umbilical  vein  endothelial  cells 
(HUVEC) and neonatal dermal microvascular endothelial cells (DMVEC) that are derived from large 
and small vessels, respectively [13]. HUVEC treated with LT become apoptotic and show a steady 
decrease in cell viability, with only 5% survival by day 3 [13,39]. Of the three major mitogen-activated 
protein kinase (MAPK) pathways disrupted by LT in HUVEC cells (ERK, p38, and JNK/SAPK), it is 
the blockade of the ERK pathway in HUVEC cells using ERK specific inhibitor PD98059 that induces 
apoptotic cell death. Inhibition of other MAPK pathways does not have this effect, which suggests that 
LT induces endothelial cell death via inhibition of the ERK pathway [13]. It has also been reported that 
the cytotoxicity of LT to HUVEC cells is associated with alterations in the expression of several genes, 
including  downregulation  of  early  growth  response-1  (Egr1)  and  X-linked  inhibitor  of  apoptosis 
protein  (Xiap),  and  upregulation  of  tumor  necrosis  factor  (TNF)-related  apoptosis-inducing  ligand 
(Trail). Modulation of these genes using protein expression vectors or inhibitory antibodies blocks  
LT-induced caspase-3 activation, consistent with their role in endothelial cell death [41].  
In contrast, even high levels of LT induce only minor increases in apoptosis and/or necrosis in 
confluent primary human lung microvascular endothelial cultures [12]. In this in vitro experimental 
system, the LT-induced decrease in transendothelial electrical resistance and increase in permeability 
to fluorescently labeled albumin is not dependent on the low levels of observed cell death [12]. The 
reason for the disagreement among these studies may be attributed to the differences of cell types, 
culture  conditions,  source  of  toxin,  and  whether  the  analysis  methods  applied  were  capable  of 
distinguishing  cell  death  and  the  general  anti-proliferative  effect  described  in  the  overview  by  
Moayeri et al. [42]. As endothelial necrosis is not a general hallmark of LT treatment [3,40], HUVEC 
cells  might  not  be  the  ideal  model  for  assessing  in  vivo  effects  of  LT.  In  this  respect,  studies 
demonstrating  enhanced  permeability  in  primary  human  lung  microvascular  endothelial  cell  
cultures [12] better mimic intoxication in vivo. In any case, a cytotoxic effect of LT on endothelial 
cells would be potentially overshadowed by the rapid and profound vascular leakage syndrome that 
occurs in LT-injected animals [3,11,40] (Figure 1). 
There is also increasing evidence that LT is able to disrupt barrier function through mechanisms 
affecting the translocation of junctional complex proteins and reorganization of cytoskeleton systems. 
LT reduces the levels of peripheral filamentous (F)-actin, increases the levels of central stress fibers, 
and  disperses  the  localization  of  vascular  endothelial  (VE)-cadherin  in  primary  human  lung 
microvascular endothelial cell cultures (Figure 2) [12]. In addition, a recent study in a LT-transgenic 
Drosophila melanogaster strain showed that LT reduces cadherin protein levels at adherens junctions 
by  directly  targeting  Rab11/Sec15  exocysts  and  thereby  disrupting  endocytic  recycling  [43].  In 
addition, ET reduces the level of cadherins by affecting the distribution of Rab11 in cytoplasm [43]. In Toxins 2011, 3                         
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cultured human brain microvascular endothelial cells (hBMECs), LT and ET synergistically act to 
inhibit formation of Sec15 vesicles and reduce cadherin protein levels  at adherens junctions [43], 
providing a potential mechanism through which the toxin facilitates the disruption of the endothelial 
barriers during infection.  
In addition, LT has both inhibitory and stimulatory effects on immune responses of endothelial 
cells, likely through a mechanism related to the cumulative effect of LT-mediated enhancement of IκB 
kinase (IKK)-NF-κB activation and suppression of the activity of activator protein-1 (AP-1) [44]. LT 
also enhances expression of vascular cell adhesion molecule-1 (VCAM-1) on TNF-activated primary 
human  endothelial  cells  [45,46].  VCAM-1  is  a  major  mediator  for  the  adhesion  of  lymphocytes, 
monocytes, eosinophils, and basophils to vascular endothelium during inflammatory response, and 
enhancement  of  its  expression  is  associated  with  vasculitis  and  barrier  dysfunction  [47,48].  
This  represents  a  potential  mechanism  through  which  LT  could  disrupt  the  endothelial  barrier  
during infection. 
5. Effect of Anthrax LT on Lung Epithelium  
5.1. Clinical Findings 
The lung epithelium serves as a poor barrier to infection following exposure through an inhalation 
route,  primarily  because  Bacillus  anthracis  usurps  host  immune  protective  mechanisms.  Bacillus 
anthracis spores are phagocytosed by pulmonary macrophages, which translocate the spores into the 
mediastinal lymph nodes where they germinate. It appears that symptoms of inhalation anthrax are 
manifested initially in response to the production of anthrax toxin. During the inhalation infections that 
occurred during the 2001 bioterrorism attacks in the United States, clinicians observed the classic 
appearance of a widened mediastinum in chest X-rays (CXR). In addition, pulmonary infiltrates and 
pleural effusions were detected via CXR and/or computed tomography (CT), while bronchoscopic 
examinations performed on some of these patients showed edematous and erythematous pulmonary 
mucosa [49]. It should be noted that nearly all these patients were experiencing Bacillus anthracis 
bacteremia at the time of these more thorough examinations. Therefore, it is likely that the mucosal 
lesions of these patients resulted from systematic bacteremia and toxemia, and were not necessarily a 
direct consequence of the initial exposure to anthrax spores. Instead, the primary pathology in the chest 
cavity is focused in the mediastinum. Autopsies from clinical cases during the Sverdlovsk outbreak in 
1979  revealed  edema  and  hemorrhagic  necrosis  of  the  thoracic  lymph  nodes  and  hemorrhagic 
mediastinitis [36,37]. In contrast, systemic administration of LT does not induce intrapulmonary or 
mediastinal  lesions,  but  leads  to  the  development  of  pleural  effusions  [3,50].  Nevertheless,  
anthrax-infected  and  anthrax  LT-treated  hosts  share  a  common  pathological  feature,  dysfunction 
and/or compromise of critical host barriers. 
5.2. Mechanisms of Action 
Apart from pulmonary edema (alveolar and interstitial, Figure 1) and non-hemorrhagic pleural fluid 
accumulation,  the  lack  of  obvious  pathological  lesions  in  the  lungs  of  LT-treated  rats  and  mice 
suggests  that  alterations in  membrane permeability do not result from  overt tissue damage in  the Toxins 2011, 3                         
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pulmonary  epithelium  [3,50].  In  the  lung,  the  primary  functional  anatomical  structure  is  the  
alveolar-capillary  membrane,  which  consists  of  alveolar  epithelial  cells  and  endothelial  cells.  The 
pulmonary  endothelial  cells  form  a  barrier  that  separates  the  blood-borne  humoral  and  cellular 
elements  of  coagulation  from  the  thrombogenic  sub-endothelial  tissues.  Endothelial  cell  damage 
exposes the basement membrane components to the blood and initiates coagulation [51]. Histological 
staining of lungs from LT-treated mice does not reveal evidence of capillary thrombosis or fibrin clots 
as seen with the disseminated intravascular coagulation (DIC) [3]. Instead, hypoalbuminemia caused 
by LT-induced liver damage was initially hypothesized to play a major role in vascular fluid leakage 
syndrome  observed  in  LT-treated  mice.  This  vascular  fluid  leakage  syndrome,  in  turn,  was 
hypothesized to lead to LT-induced hypoxia [3].  
Yet, recent in vitro studies have suggested direct effects of LT on the permeability of the pulmonary 
epithelium. LT treatment of ex vivo differentiated mucociliary human lung epithelium has been shown 
to decrease transepithelial resistance, increase barrier permeability, and lead to low level enhancement 
of epithelial cell death [52]. LT treatment impairs polarization and blocks cell motility [52]. Associated 
with  these  abnormalities  is  evidence  of  disrupted  F-actin  and  microtubule  regulation,  along  with 
altered cellular localization of the key junctional proteins, epithelial (E)-cadherin and tight junction 
protein-1 (ZO1) (Figure 2) [52]. Expression of an LT-resistant MKK1/2 mutant pair restores cellular 
polarization and motility [52]. In addition, it has been reported that exposure of human small airway 
lung epithelial cells (HSAECs) to spores of the toxigenic Sterne strain of Bacillus anthracis results in 
inhibition of AKT phosphorylation, thereby interfering with the signaling required for the assembly of 
the E-cadherin-mediated adherens junctions [53]. Moreover, exposure to a MKK1/2 specific inhibitor, 
but not a p38 inhibitor, reduces AKT phosphorylation similar to LT [53]. These findings support a 
critical  role  for  the  blockade  of  MKK1/2  signaling  in  mediating  the  effects  of  LT  on  pulmonary 
epithelial cells. 
6. Effect of Anthrax LT on Intestinal Barriers  
6.1. Clinical Findings 
As  discussed  previously,  gastrointestinal  anthrax  leads  to  ulcerative  lesions  accompanied  by 
gastrointestinal  bleeding  and  fluid  loss  (Figure  1).  However,  even  if  the  route  of  inoculation  is 
primarily not through a GI source, intestinal lesions do occur during systemic anthrax infection. For 
example,  in  the  inhalational  anthrax  outbreak  in  Sverdlovsk  in  1976,  39  out  of  42  cases  showed 
multiple gastrointestinal submucosal hemorrhagic lesions, suggesting the intestinal barrier is especially 
susceptible to Bacillus anthracis infection and/or anthrax toxin [36]. The use of animal models has 
allowed a direct analysis of the role of anthrax toxin in mediating intestinal pathology. Some of these 
effects are likely due to the action of the EF component of anthrax toxin. Mice challenged with ET 
show  intestinal  intralumenal  fluid  accumulation,  followed  by  focal  hemorrhage  in  the  ileum  [54]. 
However, LF has direct actions of gastrointestinal integrity as well. Moayeri and colleagues noted 
discolored dark red/black feces in the small and large intestines of approximately 50% of LT-treated 
BALB/c  mice  [3].  Subsequently,  our  group  demonstrated  that  LT  causes  intestinal  ulcerations  in 
BALB/c and C57BL/6 mice. These lesions are characterized by disruption of the normal architecture 
of the epithelial layer, resulting in focal areas of epithelial ulceration [10]. Toxins 2011, 3                         
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Figure 2. Schematic depiction of the effects of lethal toxin on endothelial and epithelial 
cells.  (A)  Baseline  physiological  state;  (B)  LT  targeting  leads  to  proliferation  arrest, 
cytoskeleton  rearrangement,  junctional  protein  trafficking  impairment,  and  neutrophil 
elastase-dependent cell death. Arrows depict the functional integrity of the barriers.  
 
6.2. Mechanisms of Action 
The  tissue  lesions  observed  in  the  intestinal  tracts  of  LT-treated  mice  indicate  that  LT  has  a 
profound ability to destroy the anatomic integrity of the gastrointestinal epithelium. Intestinal epithelial 
cells characteristically display rapid turnover. Under physiological conditions, approximately 60% of 
cells in the intestinal crypt divide twice daily to replenish the differentiated epithelial cells that undergo 
apoptosis and detach at the tips of the villi [55,56]. Properly regulated proliferation of these cells is 
important  to  the  integrity  of  the  intestinal  epithelial  barrier.  Therefore,  a  blockade  in  cellular 
proliferation  would  lead  to  a  disruption  of  the  intestinal  barrier  [57,58].  As  anthrax  LT  has  a  
well-documented  anti-proliferative  effect  [42],  it  follows  that  this  effect  would  contribute  to  a 
breakdown of the intestinal epithelial barrier.  
At least one host factor mediating LT-induced intestinal ulceration has been implicated. Our group 
recently reported an increase in elastase activity detected in intestinal samples from mice treated with 
LT in vivo [10] (Figure 2). This finding is in line with previous reports that LT induces neutrophilia [3], 
and serum elastase levels are elevated in mice challenged with Bacillus anthracis [59]. Neutrophil 
elastase is a critical mediator of inflammatory reactions and a key contributor to thrombohemorrhagic 
vasculopathy,  such  as  the  Shwartzman  reaction  [60].  The  central  role  of  neutrophil  elastase  in  
LT-induced intestinal pathology is highlighted by the finding that neutrophil elastase-deficient mice 
are resistant to LT-induced intestinal ulcerations and bleeding, and neutrophil elastase-deficient mice 
display improved survival compared to wild type controls (Figure 2) [10]. The potential role of other 
neutrophil factors is debatable. For example, murine neutrophils release increased superoxide in vitro Toxins 2011, 3                         
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and  ex  vivo  following  treatment  with  LT  [61],  while  human  neutrophils  treated  with  LT  and 
subsequently  stimulated  with  formylmethionylleucylphenylalanine  (FMLP)  are  characterized  by  a 
blockade in actin-based motility and superoxide production [62,63]. Moreover, it is important to note 
that direct effects of LT on neutrophils are not absolutely required for LT-induced death. Mice with 
lineage-specific mutations in the primary PA receptor, capillary morphogenesis protein-2 (CMG2), 
succumb to high doses of LT [64]; however, indirect effects of LT mediated via neutrophils are not 
excluded in this particular model. 
In addition, residential immune cells are critical cellular components of the barriers and play a key 
role  in  maintaining  barrier  function.  Intestinal  immune  cells  represent  over  25%  of  the  intestinal 
mucosa mass and 40% of total immune cells of the body [65]. Our group and others have previously 
demonstrated  that  LT  inhibits  function  and  proliferation  of  lymphocytes  [66–69].  A  link  between 
immunosuppression and the integrity of the gastrointestinal barrier during anthrax intoxication appears 
likely  in  light  of  recent  work  involving  LT-treated  MyD88-deficient  mice.  MyD88  is  a  universal 
adapter protein used by most Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs), which 
plays  a  crucial  role  in  maintaining  intestinal  epithelial  barrier  function.  LT-challenged  
MyD88-deficient  mice  show  marked  multifocal  intestinal  ulcers  and  bacteremia  with  enteric 
organisms,  suggesting  the  combination  of  immunosuppression  and  LT  compromises  the  intestinal 
epithelial barrier [70]. Moreover, LT-mediated dysregulation of immune cells may also contribute to 
barrier dysfunction by increasing bacterial translocation across the intestinal epithelium. Translocation 
of Escherichia coli or other indigenous intestinal bacterial flora to mesenteric lymph nodes (MLN) is 
significantly increased in athymic nude mice and mice depleted of T-cells [71,72]. 
7. Effect of Anthrax LT on the Blood-Brain Barrier (BBB) 
Anthrax meningitis/meningoencephalitis is the main neurological complication of anthrax infection. 
It is exhibited in up to half of the cases in outbreaks of inhalational anthrax [36,73]. In experimental 
inhalational  anthrax  infection  models  in  monkeys,  meningitis  has  occurred  in  50–77%  of  cases 
examined [38,74]. The high occurrence of meningitis in anthrax infections indicates that vegetative 
Bacillus anthracis bacteria are capable of penetrating the BBB. The BBB is formed by a single layer of 
specialized endothelial cells, known as brain microvascular endothelial cells (BMEC). These cells are 
closely  sealed  by  tight  junctions.  Bacillus  anthracis  is  able  to  invade  human  brain  microvascular 
endothelial cells and to penetrate the BBB in vitro and in vivo, but this activity is toxin-coding plasmid 
(pXO1)-dependent, as a pXO1-deficient strain exhibits significantly reduced adherent and invasive 
properties (Figure 1) [75]. The ability of anthrax toxin to facilitate the penetration of bacteria into the 
brain correlates with its action to suppress the innate defenses of the BBB [75]. Whether LT directly 
disrupts  the  BBB  structure  in  vivo  remains  to  be  explored.  Early  studies  involving  the  direct 
application of LT into the cerebrospinal fluid of monkeys via the cisterna magna resulted in the death 
of non-human primates by an unknown mechanism [76]. However, these models are not ideal for 
evaluating the effect on BBB due to the rapid death that follows injection (within 10 min). Limited  
in  vitro  data  derived from  experiments  with cultured human brain  microvascular endothelial  cells 
(hBMECs) suggest a role for LT-dependent cadherin deregulation in disrupting cellular junctions in 
the BBB [43]. Toxins 2011, 3                         
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It is also important to note that anthrax LT also has strain- and species-specific effects on the 
production of cytokines, depending on whether the animal encodes a resistant vs. susceptible allele of 
the Nalp1b gene [5]. For example, LT treatment leads to activation of caspase-1 and the release of 
activated IL-1β and IL-18 in BALB/c mice and macrophages derived from this line [3–5]. Cytokines 
such  as  IL-1β  enhance  endothelial  permeability  in  the  BBB  [77].  However,  LT-induced  cytokine 
release  is  largely  absent  in  strains  and  species  with  resistant  alleles  of  Nalp1b,  indicating  that  
LT-induced disruption of endothelial barriers occurs through mechanisms independent of cytokine 
production as well [5]. LT might synergize with other pathogenic factors, such as Bacillus anthracis  
S-layer protein A (BslA). This newly identified pXO1-encoded protein is likely to play a critical role 
in breakdown of the BBB by  Bacillus anthracis, as mice challenged with BslA-deficient Bacillus 
anthracis exhibit a significant decrease in the frequency of brain infections compared to mice injected 
with the parental Sterne strain [78,79].  
8. Final Remarks 
It has been well documented that LT disrupts the anatomic and functional integrity of critical host 
barriers. These effects not only allow Bacillus anthracis to establish infection, but also they are leading 
contributors  to  morbidity  and  mortality.  A  central  theme  of  recent  studies  is  that  LT  causes 
dysregulation of junctional complexes by altering the localization of key junction associated proteins, 
including the cadherins and ZO1 [12,52]. Intriguing new data suggest that the blockade in cadherin 
trafficking, in turn, results from the activity of LT to directly target Rab11/Sec15 exocysts and thereby 
disrupt endocytic recycling [43].  
Nevertheless, important questions remain to be addressed, including whether other pathogen- and 
host-associated factors work in concert with LT. For example, administration of lethal doses of edema 
toxin (ET) into mice leads to extensive pathological lesions in a broad range of organ/tissues including 
barrier tissues [54]. In addition, ET and LT have unique effects on cardiovascular and renal function in 
a canine model of intoxication [80]. These effects act synergistically. Other uncharacterized Bacillus 
anthracis-derived  factors  may  also  contribute  to  the  pathology  in  barrier  tissues  (e.g.,  BslA). 
Investigation of the interactions of these bacterial factors with LT should be undertaken to assess the 
overall effect of LT in vivo. It will also be important to delineate the MKK pathways targeted by LT 
that  underlie  toxic  effects  on  host  barriers.  In  this  regard,  the  MKK1/2  pathways  appear  to  be 
promising candidates. 
Although  important  strides  have  been  made  toward  understanding  the  mechanisms  underlying  
LT-induced barrier dysfunction, we have much to learn regarding the exact molecular and cellular 
interactions between LT and toxin-targeted host barrier tissues. It will be critical to determine whether 
the effects of anthrax LT on junctional complexes represent critical and universal mechanisms that 
would amenable to therapeutic targeting. With regard to the potential to develop anthrax therapies, 
treatment  strategies  for  anthrax  infection  have  focused  thus  far  on  antibiotics  and,  more  recently, 
upstream anti-toxin therapeutics (e.g., neutralizing polyclonal and monoclonal anti-toxin antibodies, 
receptor  binding  inhibitors,  and  LF  enzyme  inhibitors)  [81,82].  A  consideration  of  downstream 
therapeutic targets such as those associated with toxin-induced barrier dysfunction might provide new 
possibilities for therapies that are effective, even if delayed in their administration following infection. Toxins 2011, 3                         
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Moreover, it is important to note that Bacillus anthracis is just one of several enteric pathogens that 
disrupt  MAPK  signaling  as  a  virulence  mechanism.  Virulence  factors  of  Shigella,  Yersinia  and 
Salmonella  also  target  and  inactivate  MAPK  signaling  pathways  [83–86].  For  this  reason,  it  is 
reasonable to speculate that an improved understanding of the role of the three major MAPK signaling 
pathways  in  maintaining  barrier  function  will  not  only  have  therapeutic  implications  for  anthrax 
infection, but for a variety of other infectious diseases and inflammatory bowel conditions as well. 
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